EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.

[1]  R. Hájek,et al.  PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017 , 2017, Immunology.

[2]  D. Grandér,et al.  PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma , 2017, Leukemia.

[3]  Wen-Qi Jiang,et al.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma , 2016, Journal of Hematology & Oncology.

[4]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Kui Wu,et al.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. , 2016, Blood.

[6]  D. Heo,et al.  Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas , 2016, Histopathology.

[7]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[8]  K. Akashi,et al.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.

[9]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[10]  S. Steinberg,et al.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. , 2015, Blood.

[11]  W. Xu,et al.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age , 2015, Scientific Reports.

[12]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[13]  E. Hawkes,et al.  Programmed cell death-1 inhibition in lymphoma. , 2015, The Lancet. Oncology.

[14]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[15]  Y. Zu,et al.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Young,et al.  EBV-positive diffuse large B-cell lymphoma of the elderly. , 2013, Blood.

[17]  M. Shipp,et al.  PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.

[18]  J. Feuillard,et al.  B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels , 2012, The Journal of Immunology.

[19]  L. Medeiros,et al.  EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. , 2011, Clinical lymphoma, myeloma & leukemia.

[20]  G. Pinkus,et al.  Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.

[21]  G. Lenz,et al.  Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells , 2010, Proceedings of the National Academy of Sciences.

[22]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[23]  L. Xerri,et al.  Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. , 2008, Human pathology.

[24]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[25]  C. Klein,et al.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.

[26]  W. Hammerschmidt,et al.  Latent membrane protein 1 of Epstein–Barr virus coordinately regulates proliferation with control of apoptosis , 2005, Oncogene.

[27]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.